StemoniX Selected as a 2017 Red Herring Top 100 Global Winner
Pasadena, California — Red Herring announced its Top 100 Global in recognition of the leading private companies from North America, Europe, and Asia, celebrating these startups’ innovations and technologies across their respective industries.
Red Herring’s Top 100 Global list has become a mark of distinction for identifying promising companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.
“Choosing the companies with the strongest potential was by no means a small feat,” said Alex Vieux, publisher and CEO of Red Herring. “After rigorous contemplation and discussion, we narrowed our list down from hundreds of candidates from across the globe to the Top 100 Winners. We believe StemoniX embodies the vision, drive and innovation that define a successful entrepreneurial venture. StemoniX should be proud of its accomplishment.”
StemoniX® transforms human induced Pluripotent Stem Cells (iPSC) into functioning microHeart® and microBrain® platforms for disease modeling and drug discovery and development. Their innovative technology allows medicines to be tested and perfected on individual human tissues before actual testing in humans. StemoniX is currently involved in partnerships with several organizations including Pairnomix™ to model epilepsy and the US military to study viral infections.
Red Herring’s editorial staff evaluated the companies on both quantitative and qualitative criteria, such as financial performance, technology innovation, management quality, strategy, and market penetration. This assessment of potential is complemented by a review of the track records and standing of startups relative to their peers, allowing Red Herring to see past the “buzz” and make the list a valuable instrument of discovery and advocacy for the most promising new business models from around the world.
“It was such an honor to be chosen as a Red Herring Top 100 Global winner,” said Ping Yeh, the CEO and inspiration behind StemoniX. “Our driving goal is to make medicine safer and more effective for everyone. I am so grateful to our investors who make it possible for us to develop our product and continue our mission and to my team for their commitment to quality and improving technology. We are partnering with pharmaceutical and research organizations to discover and develop more effective and safer medicines for diseases from Alzheimer’s to Zika Virus.”
Yeh, a cancer survivor, conceived StemoniX after he was told by his doctors that the chemotherapy necessary to destroy his cancer may also destroy his heart. As an expert in microengineering, he realized that there had to be a better way to test the safety of medications, thus StemoniX was born. The StemoniX microHeart® and microBrain® platforms have altered how new medications are discovered, providing a human template for testing and treating human diseases.
Read More from Red Herring here.
StemoniX® is transforming how medicine is discovered. By using skin or blood to create functioning microHearts® and microBrains®, StemoniX is making it possible to test medication on humans without that medication ever entering their bodies. This method of drug testing will speed up the search for new cures and enable the ability to test drug effectiveness on an individual person, so medicine works correctly the first time. For more information visit www.stemonix.com.
Interested in getting in touch? Send us an email email@example.com or fill out a contact form and we will be happy to get back to you.